Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma in a Japanese population

Cancer Letters

Volumn 241, Issue 1, 2006, Pages 59-63

  Awakura, Yasuo ^a   Ito, Noriyuki ^a   Nakamura, Eijiro ^a   Takahashi, Takeshi ^a   Kotani, Hirokazu ^b   Mikami, Yoshiki ^b   Manabe, Toshiyuki ^b   Kamoto, Toshiyuki ^a   Habuchi, Tomonori ^c   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Kidney; MMP 9; Polymorphisms; Renal cell carcinoma; Risk

Indexed keywords

GELATINASE B; PRIMER DNA;

ADULT; AGED; ARTICLE; ENZYMOLOGY; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; JAPAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CARCINOMA, RENAL CELL; DNA PRIMERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JAPAN; KIDNEY NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 33847791212     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.10.005     Document Type: Article

References (23)

1. Dhote R., Pellicer-Coeuret M., Thiounn N., Debre B., Vidal-Trecan G. Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. Br. J. Urol. Int. 2000, 86:20-27.
2. Ajiki W., Tsukuma H., Oshima A. Cancer incidence and incidence rates in Japan in 1999: estimates based on data from 11 population-based cancer registries. Jpn. J. Clin. Oncol. 2004, 34:352-356.
3. Chow W.H., Devesa S.S., Warren J.L., Fraumeni F. Rising incidence of renal cell cancer in the United States. J. Am. Med. Assoc. 1999, 281:1628-1631.
4. Ozdemir E., Kakehi Y., Nakamura E., Kinoshita H., Terachi T., Okada Y., et al. HLA-DRB1 0101 and 0405 as protective alleles in Japanese patients with renal cell carcinoma. Cancer Res. 1997, 57:742-746.
5. Nakamura E., Megumi Y., Kobayashi T., Kamoto T., Ishitoya S., Terachi T., et al. Genetic polymorphisms of the interleukin-4 receptor alpha gene are associated with an increasing risk and a poor prognosis of sporadic renal cell carcinoma in a Japanese population. Clin. Cancer Res. 2002, 8:2620-2625.
6. Siegsmund M., Brinkmann U., Schaffeler E., Weirich G., Schwab M., Eichelbaum M. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol. 2002, 13:1847-1854.
7. Hirata H., Naito K., Yoshihiro S., Matsuyama H., Suehiro Y., Hinoda Y. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma. Int. J. Cancer 2003, 106:372-374.
8. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
9. Ghilardi G., Biondi M.L., Caputo M., Leviti S., DeMonti M., Guagnellini E., et al. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin. Cancer Res. 2002, 8:3820-3823.
10. Yu C., Pan K., Xing D., Liang G., Tan W., Zhang L., et al. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res. 2002, 62:6430-6433.
11. Kallakury B.V., Karikehalli S., Haholu A., Sheehan C.E., Azumi N., Ross S. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin. Cancer Res. 2001, 7:3113-3119.
12. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
13. Zhang B., Henney A., Eriksson P., Hamsten A., Watkins H., Ye S. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum. Genet. 1999, 105:418-423.
14. Storkel S., Eble J.N., Adlakha K., Amin M., Blute M.L., Bostwick G., et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997, 80:987-989.
15. Guinan P., Sobin L.H., Algaba F., Badellino F., Kameyama S., MacLennan G., et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997, 80:992-993.
16. Goldstein N.S. Grading of renal cell carcinoma. Urol. Clin. North Am. 1999, 26:637-642.
17. Morgan A.R., Zhang B., Tapper W., Collins A., Ye S. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J. Mol. Med. 2003, 81:321-326.
18. Mejean A., Oudard S., Thiounn N. Prognostic factors of renal cell carcinoma. J. Urol. 2003, 169:821-827.
19. Yamada Y., Ando F., Niino N., Shimokata H. Association of a polymorphism of the matrix metalloproteinase-9 gene with bone mineral density in Japanese men. Metabolism 2004, 53:135-137.
20. Kim J.S., Park H.Y., Kwon J.H., Im E.K., Choi D.H., Jang S., et al. The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina. Yonsei Med. J. 2002, 43:473-481.
21. Matsumura S., Oue N., Nakayama H., Kitadai Y., Yoshida K., Yamaguchi Y. A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J. Cancer Res. Clin. Oncol. 2005, 131:19-25.
22. Masuda H., Kurita Y., Suzuki A., Kanbayashi T., Suzuki K., Fujita K. Prognostic factors for renal cell carcinoma: a multivariate analysis of 320 cases. Int. J. Urol. 1997, 4:247-253.
23. Onodera Y., Matsuda N., Ohta M., Goto R., Fujii N., Yamada Y. Prognostic significance of tumor grade for renal cell carcinoma. Int. J. Urol. 2000, 7:4-9.